Parkinson's Treatment Denied: How to Appeal

Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting movement, balance, and increasingly cognition and autonomic function. For patients whose symptoms are inadequately controlled by oral medications, advanced therapies — including Deep Brain Stimulation (DBS) surgery, Duopa (carbidopa/levodopa intestinal gel), and focused ultrasound — can dramatically improve motor function and quality of life. Insurance denials for Parkinson's treatments and rehabilitative services are a serious and growing problem. Here is how to build an effective appeal.

Parkinson's Treatments Subject to Denial

Deep Brain Stimulation (DBS) — neurosurgical implantation of electrodes in the subthalamic nucleus or globus pallidus, connected to a pulse generator in the chest. FDA-approved for Parkinson's disease. Covered by Medicare and most commercial insurance when eligibility criteria are met, but Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization is required and denials occur.

Duopa (carbidopa/levodopa enteral suspension) — a gel formulation of carbidopa/levodopa delivered continuously via a surgically placed jejunal tube (J-tube) through a PEG-J system. Approved for advanced PD with persistent motor fluctuations ("off" episodes) despite optimized oral levodopa therapy. Expensive (approximately $80,000–100,000 per year) and frequently denied.

Focused ultrasound (Exablate Neuro) — FDA-approved for essential tremor and unilateral thalamic DBS-equivalent intervention for PD tremor. Newer and less widely covered; may be denied as experimental despite FDA approval.

Speech therapy — essential for dysarthria (speech impairment) and dysphagia (swallowing difficulty), both common in PD. Lee Silverman Voice Treatment (LSVT LOUD) is an evidence-based program frequently denied.

Physical and occupational therapy — critical for maintaining mobility, balance, and fall prevention. PT with Parkinson's-specific protocols (LSVT BIG, PWR!Moves) may be denied for "failure to improve" if insurers misapply the improvement standard.

Levodopa adjustments and combination medications — occasionally denied as "too frequent" or "not indicated" when changes are clearly clinically justified.

Why Insurers Deny Parkinson's Treatments

DBS: eligibility criteria disputes. Coverage criteria for DBS in PD typically require: diagnosis of idiopathic PD (not atypical parkinsonism), good levodopa responsiveness (at least 30% improvement in motor UPDRS with levodopa), significant disability from motor fluctuations or dyskinesias despite optimized medication, absence of significant dementia, and adequate general health for surgery. Denials cite failure to meet one or more of these criteria — often based on incomplete or incorrectly submitted documentation.

Duopa: inadequate "off" time documentation. Payers require documentation of severe and disabling motor fluctuations ("off" periods) despite optimized oral levodopa regimen (typically 4–5 doses per day). Continuous ambulatory motor monitoring or formal UPDRS "off/on" assessments with an "off" time of 2+ hours per day despite optimized oral therapy are typical requirements.

Therapy denials: "maintenance" vs. "improvement." Insurers may deny continued PT/OT/speech therapy arguing that the patient has "plateaued" and therapy is only "maintaining" function rather than producing measurable improvement. This is an incorrect application of the legal standard — the Supreme Court's Jimmo v. Sebelius settlement (2013) clarified that Medicare's skilled therapy coverage does not require improvement; it requires skilled care to maintain function or prevent or slow decline. This applies to commercial plans that mirror Medicare standards. Cite Jimmo v. Sebelius explicitly in therapy appeals.

Focused ultrasound: experimental label. Exablate Neuro for PD tremor may be labeled experimental by some payers despite FDA approval; argue as with any FDA-approved treatment that it is definitively not experimental.

Building Your Clinical Appeal

DBS Appeals

Submit: current medications with doses and timing, UPDRS Part III scores in both "on" and "off" states (documenting levodopa responsiveness), a detailed description of motor fluctuations and dyskinesias, neurologist attestation that the patient meets DBS candidacy criteria, and surgical team documentation of surgical fitness. If a multidisciplinary DBS team evaluation was performed (standard of care at academic centers), include the team's conclusions.

Cite the Movement Disorder Society (MDS) evidence-based review of DBS for PD, which endorses DBS for carefully selected patients with motor fluctuations and tremor not controlled by medication.

Duopa Appeals

Document daily "off" time using a motor diary (Hauser Diary) over at least 3 days — this is the standard clinical tool. Submit the diary data showing 2+ hours of "off" time per day despite optimized oral levodopa (document the oral regimen, doses, and timing). Include your neurologist's or movement disorder specialist's letter confirming the optimization process and clinical judgment.

Therapy Appeals: Cite Jimmo v. Sebelius

For PT/OT/speech therapy denials citing plateau or maintenance-only care:

"Under the terms of the Jimmo v. Sebelius settlement (Civil Action No. 5:11-cv-17, D. Vt. 2013), Medicare's coverage standard for skilled therapy does not require that the patient must be improving. Coverage is required when skilled care is needed to maintain the patient's current level of function or to prevent or slow further deterioration. [Patient name]'s skilled [therapy type] is medically necessary to prevent further decline in [gait/speech/swallowing/balance] function consistent with Parkinson's disease progression."

Commercial plans that use Medicare-like standards must apply this same standard.

LSVT LOUD for Speech

Lee Silverman Voice Treatment (LSVT LOUD) is an evidence-based speech therapy protocol with Level 1 evidence for PD. If denied as "not medically necessary," cite the clinical trial data and the fact that LSVT LOUD is endorsed by the Parkinson's Foundation and the MDS.

Resources

• Parkinson's Foundation (parkinson.org) — helpline (1-800-4PD-INFO), insurance navigation guides, care advisor program
• American Parkinson Disease Association (APDA) (apdaparkinson.org) — local chapters and information centers
• Michael J. Fox Foundation — research and patient advocacy resources
• Movement Disorder Society (MDS) — clinical practice guidelines and evidence reviews

Parkinson's treatment denials are winnable with the right clinical documentation, especially when a movement disorder specialist is engaged and Jimmo v. Sebelius is cited for therapy denials.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word. Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?